Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis

Arthritis and Rheumatism

Volumn 64, Issue 10, 2012, Pages 3452-3462

  Lionaki, Sophia ^a,b   Blyth, Elizabeth R ^a   Hogan, Susan L ^a   Hu, Yichun ^a   Senior, Brent A ^a   Jennette, Caroline E ^a   Nachman, Patrick H ^a   Jennette, J Charles ^a   Falk, Ronald J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ADULT; ANCA ASSOCIATED VASCULITIS; ANCA WITH SPECIFICITY FOR MYELOPEROXIDASE VERSUS ANCA WITH SPECIFICITY FOR PROTEINASE 3; ANTIBODY SPECIFICITY; ARTICLE; CHAPEL HILL CONSENSUS CONFERENCE; DEATH; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; EUROPEAN MEDICINES AGENCY; FEMALE; FOLLOW UP; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK ASSESSMENT; TREATMENT REFUSAL; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODY SPECIFICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOBLASTIN; PEROXIDASE; PROGNOSIS;

EID: 84869025741     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34562     Document Type: Article

References (50)

1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37: 187-92. (Pubitemid 24065492)
2. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-7. (Pubitemid 46226058)
3. Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990; 33: 1135-6. (Pubitemid 20273299)
4. Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DR, Jennette JC, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63: 863-4.
5. Kallenberg CG. Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep 2010; 12: 399-405.
6. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 621-31.
7. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 23-32. (Pubitemid 26067088)
8. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibodyassociated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-9. (Pubitemid 26067089)
9. Burnham KP, Anderson DR. Model selection and multimodal inference: a practical information-theoretic approach. 2nd ed. New York: Springer-Verlag; 2002.
10. Anderson DR. Model base inference in the life sciences: a primer on evidence. New York: Springer; 2008.
11. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008;58: 2908-18.
12. Fauci AS, Haynes B, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978; 89: 660-76. (Pubitemid 9037756)
13. De Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018-27. (Pubitemid 32970564)
14. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-84. (Pubitemid 36396745)
15. Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56: 467-83. (Pubitemid 16221674)
16. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, de Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47: 326-32. (Pubitemid 34627702)
17. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005; 352: 330-2.
18. Brockmann H, Schwarting A, Kriegsmann J, Petrow P, Gaumann A, Muller KM, et al. Proteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis. Arthritis Res 2002; 4: 220-5. (Pubitemid 34460763)
19. Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and the UK - are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 2008; 23: 3928-31.
20. Chen M, Cui Z, Zhao MH. ANCA-associated vasculitis and anti-GBM disease: the experience in China. Nephrol Dial Transplant 2010; 25: 2062-5.
21. Hogan SL, Cooper GS, Savitz DA, Nylander-French LA, Parks CG, Chin H, et al. Association of silica exposure with antineutrophil cytoplasmic autoantibody small-vessel vasculitis: a population- based, case-control study. Clin J Am Soc Nephrol 2007;2: 290-9.
22. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol 2003; 132: 496-504. (Pubitemid 36713957)
23. Ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002; 36: 130-47. (Pubitemid 34055784)
24. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, et al. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant 2007; 22: 3508-15. (Pubitemid 350212510)
25. Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, Liu Y, et al. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int 2007; 72: 853-64. (Pubitemid 47462069)
26. Lionaki S, Falk RJ. Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis. J Am Soc Nephrol 2007;18: 1987-9. (Pubitemid 47041059)
27. Bautz DJ, Preston GA, Lionaki S, Hewins P, Wolberg AS, Yang JJ, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008; 19: 2421-9.
28. Yang J, Bautz DJ, Lionaki S, Hogan SL, Chin H, Tisch RM, et al. ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 2008; 74: 1159-69.
29. Kobayashi K, Shibata T, Sugisaki T. Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. Kidney Int 1995; 47: 454-63.
30. Heeringa P, Brouwer E, Klok PA, Huitema MG, Van Den Born J, Weening JJ, et al. Autoantibodies to myeloperoxidase aggravate mild anti-glomerular- basement-membrane-mediated glomerular injury in the rat. Am J Pathol 1996; 149: 1695-706. (Pubitemid 26363975)
31. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloper- oxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-63.
32. Smyth CL, Smith J, Cook HT, Haskard DO, Pusey CC. Antimyeloperoxidase associated pauci-immune focal segmental glomerulonephritis in rats [abstract]. Cleve Clin J Med 2002;69: SII-156.
33. Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005; 167: 39-45. (Pubitemid 40884768)
34. Huugen D, Cohen Tervaert JW, Heeringa P. TNF-bioactivityinhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clin J Am Soc Nephrol 2006;1: 1100-7.
35. Sinico RA, Gregorini G, Radice A, Campanini M, Pozzi C, Quarenghi M, et al. Clinical significance of autoantibodies to myeloperoxidase in vasculitic syndromes. Contrib Nephrol 1991; 94:31-7.
36. Geffriaud-Ricouard C, Noel LH, Chauveau D, Houhou S, Grunfeld JP, Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39: 125-36. (Pubitemid 23093348)
37. Guillevin L, Visser H, Noel LH, Pourrat J, Vernier I, Gayraud M, et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg- Strauss syndrome: 62 patients. J Rheumatol 1993; 20: 1345-9. (Pubitemid 23310987)
38. Cohen Tervaert JW, Van Der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149: 2461-5. (Pubitemid 19283202)
39. Nolle B, Specks U, Ludemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 1989;111: 28-40. (Pubitemid 19167594)
40. Weber MF, Andrassy K, Pullig O, Koderisch J, Netzer K. Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. J Am Soc Nephrol 1992; 2: 1227-34.
41. Chen M, Kallenberg CG, Zhao MH. ANCA-negative pauciimmune crescentic glomerulonephritis. Nat Rev Nephrol 2009;5: 313-8.
42. Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005;20: 1392-9. (Pubitemid 41430612)
43. Kyndt X, Reumaux D, Bridoux F, Tribout B, Bataille P, Hachulla E, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106:527-33. (Pubitemid 29231103)
44. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371-80. (Pubitemid 27114101)
45. Kamali S, Erer B, Artim-Esen B, Gul A, Ocal L, Konice M, et al. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients. J Rheumatol 2010; 37: 374-8.
46. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19: 1403-11. (Pubitemid 38786731)
47. Little MA, Nightingale P, Verburgh CA, Hauser T, de Groot K, Savage C, et al, on behalf of the European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: 1036-43.
48. Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ, et al. Antiproteinase 3- and antimyeloperoxidaseassociated vasculitis. Kidney Int 2000; 57: 2195-206.
49. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
50. Lim LC, Taylor JG III, Schmitz JL, Folds JD, Wilkman AS, Falk RJ, et al. Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology: comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. Am J Clin Pathol 1999; 111: 363-9. (Pubitemid 29102745)